ANVS May 2024 5.000 call
| Previous close | 3.6000 |
| Open | 2.6100 |
| Bid | 2.5500 |
| Ask | 3.8000 |
| Strike | 5.00 |
| Expiry date | 2024-05-17 |
| Day's range | 2.6100 - 2.6100 |
| Contract range | N/A |
| Volume | |
| Open interest | 52 |
GlobeNewswireAnnovis Announces New Publication in a Peer-Reviewed Journal
MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases. “This publication is a t
ZacksAmgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
ZacksKodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
